Invasive pneumococcal disease (IPD) is responsible for substantial clinical and economic burden in adults. Despite the safety and effectiveness of pneumococcal vaccines in protecting against these serious infections, immunization of eligible adults remains largely underused. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has recently expanded the use of the pneumococcal vaccine to include adults with asthma and all cigarette smokers, in addition to persons previously designated as at-risk. Improving adult pneumococcal immunization rates will require efforts from a broad range of healthcare providers. Clinicians should take a proactive approach in recommending the vaccine to eligible adults and should implement strategies that remove barriers to immunization efforts.
From the *Division of Infectious Disease, Summa Health System, Akron, OH; †Infectious Disease Section, Northeast Ohio Medical University, Rootstown, OH; ‡Department of Pharmacy Practice, Samford University McWhorter School of Pharmacy, Birmingham, AL; §Minneapolis VA Medical Center, Minneapolis, MN; ∥University of Minnesota, Minneapolis, MN; and ¶Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN.
Correspondence to: William Schaffner, MD, Professor and Chair, Department of Preventive Medicine, Vanderbilt University School of Medicine, Village at Vanderbilt-Suite 2600, 1500 21st Avenue South, Nashville, TN 37212. E-mail: email@example.com.
This publication is based on an expert roundtable discussion held in October 2011 titled “Preventing Adult Pneumococcal Disease: Know Your Options.”